| Austedo (deutetrabenazine) / Teva |
ChiCTR2300077341: Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients with Chorea Associated with Huntington’s Disease |
|
|
| Not yet recruiting | 4 | 50 | | None | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Enterprise self-funded | Chorea Associated with Huntington’s Disease | | | | |
| Terminated | 3 | 44 | Europe, US, RoW | TEV-50717, Deutetrabenazine, SD-809 | Teva Branded Pharmaceutical Products R&D, Inc. | Cerebral Palsy, Dyskinetic | 02/23 | 02/23 | | |
NCT04713982: Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease |
|
|
| Recruiting | 2/3 | 30 | US | Deutetrabenazine, Austedo | Vanderbilt University Medical Center, Teva Branded Pharmaceutical Products R&D, Inc. | Huntington Disease | 08/24 | 04/25 | | |
AUDYT, NCT04173260: An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia |
|
|
| Completed | 1/2 | 15 | US | Deutetrabenazine 6 MG | University of Pennsylvania, Teva Branded Pharmaceutical Products R&D, Inc. | Dystonia, Primary | 03/24 | 08/24 | | |
NCT04301726: Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD |
|
|
| Not yet recruiting | 1 | 48 | NA | Deutetrabenazine Oral Tablet [Austedo], Austedo, Placebo oral tablet, Placebo | Fundacion Huntington Puerto Rico | Huntington Disease | 04/22 | 12/22 | | |
ChiCTR2300076925: An Open-Label, Single Dose Trial to Characterize the Pharmacokinetics of Deutetrabenazine and its Active Metabolites in Healthy Chinese Participants After a Single Dose of a 12-mg AUSTEDO® Tablet |
|
|
| Recruiting | 1 | 20 | | On day 1 (visit 2), healthy participants will be administered a 12-mg tablet of TEV-50717 under fed conditions. | West China Hospital of Sichuan University; Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc. | Healthy Chinese Participants | | | | |
NCT04071639: Symptomatic Therapy for Patients With Huntington's Disease |
|
|
| Recruiting | 1 | 60 | RoW | Haloperidol 2Mg Tab, Haloperidol Tables, H31021234, Risperidone 1Mg Tab, Risperidone, H20010309, Zoloft 50Mg Tablet, Sertraline Hydrochloride Tablets, H10980141, Idebenone, Idebenone,H10970363, Deutetrabenazine Oral Tablet [Austedo], Deutetrabenazine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Huntington Disease | 12/24 | 12/24 | | |